While initiatives to build a drug discovery innovation ecosystem are being strengthened, the environment surrounding the domestic ethical pharmaceuticals market is becoming increasingly challenging year by year due to the promotion of continuous healthcare cost-containment measures, including drug price revisions.In terms of medical information provision activities, approaches have diversified through the increased utilization of digital technologies following the COVID-19 pandemic, and further changes are anticipated driven by the promotion of work-style reforms for physicians. Under these circumstances, our Group aims to achieve growth by promoting the widespread adoption of new drugs.
Through the stable supply of quality pharmaceutical products, we are working to maximize product value by contributing to the treatment of the many patients who need our products.
Establishing a presence in designated fields
In line with the FC strategy of concentrating resources in the fields of respiratory, otolaryngology, and urology, our approximately 600 MRs are providing, gathering, and transmitting information to medical practitioners regarding the appropriate use of pharmaceuticals with the aim of establishing a presence in these fields. For our marketing structure, in 1998, we introduced a “team structure,” with teams based in secondary medical care areas (where multiple MRs are responsible for a designated area), and are using area management in which teams cultivate their own areas. Going forward, we will create a framework for teams to assist one another and achieve their targets by refining our activities to address increasingly diverse medical needs swiftly and systematically.